In conclusion, the present work demonstrates for the first time that transfection with pSup-Smad7 siRNA can effectively inhibit ECM deposits of HTM treated with TGF-β2 in vitro which indicates it can be novel target for treatment of POAG. The gene discussed is SMAD7; the disease is open-angle glaucoma.